TP53 and diffuse large B-cell lymphoma: As described above, TP53 alterations lead to inferior responsiveness, and DLBCL patients with tumors harboring TP53 alterations had inferior outcomes following CD19-directed CAR-T immunotherapy, especially in subjects who received genetically modified T cells with a second-generation CAR comprising a 4-1BB costimulation domain (60).